Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.
Mark A. Socinski
Advertisement
Articles by Mark A. Socinski
Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses challenges facing immunotherapy combinations in patients with non–small cell lung cancer (NSCLC).
Advertisement
Latest Updated Articles
Dr. Socinski on Challenges Facing Immunotherapy CombinationsFebruary 2nd 2017
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
3
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
4
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
5